Richard Law
Stock Analyst at Goldman Sachs
(0.49)
# 3,865
Out of 4,711 analysts
51
Total ratings
n/a
Success rate
-2.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRUS Merus | Initiates: Buy | $73 | $41.85 | +74.43% | 1 | Nov 21, 2024 | |
| CLDX Celldex Therapeutics | Initiates: Neutral | $45 | $25.14 | +79.00% | 1 | Sep 30, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $25 → $31 | $19.03 | +62.90% | 2 | Sep 12, 2024 | |
| MLYS Mineralys Therapeutics | Initiates: Buy | $30 | $12.34 | +143.11% | 5 | Apr 2, 2024 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $24 | $6.10 | +293.44% | 4 | Apr 2, 2024 | |
| RCKT Rocket Pharmaceuticals | Initiates: Neutral | $39 | $11.56 | +237.37% | 1 | Apr 2, 2024 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Neutral | $62 | $52.17 | +18.84% | 1 | Apr 2, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Neutral | $11 | $6.93 | +58.73% | 4 | Aug 11, 2023 | |
| VERV Verve Therapeutics | Reiterates: Neutral | $31 | $5.74 | +440.07% | 2 | Aug 11, 2023 | |
| BEAM Beam Therapeutics | Maintains: Neutral | $46 → $47 | $29.01 | +62.01% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $40.72 | +54.72% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $40.66 | -9.00% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $12.18 | +523.97% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $1.31 | +968.70% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $18.48 | +230.09% | 4 | May 8, 2023 |
Merus
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $41.85
Upside: +74.43%
Celldex Therapeutics
Sep 30, 2024
Initiates: Neutral
Price Target: $45
Current: $25.14
Upside: +79.00%
Viridian Therapeutics
Sep 12, 2024
Maintains: Buy
Price Target: $25 → $31
Current: $19.03
Upside: +62.90%
Mineralys Therapeutics
Apr 2, 2024
Initiates: Buy
Price Target: $30
Current: $12.34
Upside: +143.11%
Olema Pharmaceuticals
Apr 2, 2024
Initiates: Buy
Price Target: $24
Current: $6.10
Upside: +293.44%
Rocket Pharmaceuticals
Apr 2, 2024
Initiates: Neutral
Price Target: $39
Current: $11.56
Upside: +237.37%
MoonLake Immunotherapeutics
Apr 2, 2024
Initiates: Neutral
Price Target: $62
Current: $52.17
Upside: +18.84%
Monte Rosa Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $6.93
Upside: +58.73%
Verve Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $31
Current: $5.74
Upside: +440.07%
Beam Therapeutics
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $29.01
Upside: +62.01%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $40.72
Upside: +54.72%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $40.66
Upside: -9.00%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $12.18
Upside: +523.97%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $1.31
Upside: +968.70%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $18.48
Upside: +230.09%